Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)

China flag China · Delayed Price · Currency is CNY
6.38
+0.03 (0.47%)
May 19, 2026, 10:15 AM CST
Market Cap3.99B +24.6%
Revenue (ttm)669.64M -13.7%
Net Income-130.94M
EPS-0.21
Shares Out627.62M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,970,723
Average Volume30,299,033
Open6.40
Previous Close6.35
Day's Range6.32 - 6.41
52-Week Range5.30 - 10.07
Beta0.51
RSI47.78
Earnings DateApr 29, 2026

About SHE:300639

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/i... [Read more]

Sector Healthcare
Founded 2003
Employees 2,205
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300639
Full Company Profile

Financial Performance

In 2025, SHE:300639's revenue was 669.64 million, a decrease of -17.89% compared to the previous year's 815.53 million. Losses were -130.94 million, -80.01% less than in 2024.

Financial Statements